Reteplase is a recombinant protein and the active ingredient in the medicinal product Rapilysin, used for thrombolytic treatment of myocardial infarction.
Except in US and Canada, Actavis owns rights on the Reteplase production process and on Rapilysin for European and worldwide distribution.
In June 2008, Scil Proteins has partnered with Roche for process transfer and manufacture of Reteplase.
Actavis, a generic pharmaceutical company is specialized in the development, manufacture and sale of generic pharmaceuticals.